Salt Lake Life Science Angels
Salt Lake Life Science Angels (SLLSA) is a not-for-profit organization based in Salt Lake City, Utah, founded in 2006 to promote investment in seed-stage healthcare and life science companies in Utah and the Mountain West. Comprising approximately twenty accredited executives, entrepreneurs, scientists, and clinicians, SLLSA focuses on identifying and supporting early-stage ventures in sectors such as life sciences, medical devices, pharmaceuticals, healthcare information technology, and biotechnology. The organization aims to benefit both its members and the local start-up community by facilitating connections and investment opportunities.
Tute Genomics
Seed Round in 2014
Tute Genomics is a cloud-based clinical genome interpretation platform based in Provo, Utah, founded in 2012. The company specializes in providing advanced analytical methods for genome analysis, utilizing proprietary machine-learning algorithms to facilitate the analysis and interpretation of entire human genomes. By enabling researchers and clinicians to leverage human genome data, Tute Genomics supports scientific discovery and the development of personalized treatment options. Its platform is designed to help physicians identify genes and biomarkers, ultimately advancing personalized medicine in the life sciences sector.
Olive Medical Corporation
Seed Round in 2011
Olive Medical Corporation, a Salt Lake City, UT based medical device manufacturing company, is dedicated to providing affordable HD MIS imaging equipment to the OR. The TCK1 HD Camera Head and OVB1 HD Camera Control Unit introduces affordable “True HD” MIS visualization with intuitive controls and light weight ergonomics. Using a combination of superior technology, cutting-edge imaging sensors and lean manufacturing processes, Olive Medical’s visualization system fits all cost containment needs. Olive Medical manufacturing is based in the United States.
Veritract
Series A in 2011
Veritract is focused on enhancing the safety and effectiveness of feeding tube placement in the gastrointestinal tract. Each year, approximately 3,000 individuals in the United States suffer fatal outcomes due to improperly placed feeding tubes. To address this critical issue, Veritract has developed innovative feeding tubes that incorporate integrated optics and steering capabilities. This technology enables precise placement and real-time confirmation of tube positioning through direct vision, allowing healthcare professionals to inspect and monitor internal organs with greater accuracy. By improving the precision of feeding tube placement, Veritract aims to significantly reduce the risk of unnecessary deaths and serious health complications associated with current feeding tube procedures.
VisualShare
Angel Round in 2010
VisualShare, Inc. is a provider of software solutions designed for image exchange, management, and collaboration, primarily serving the medical, biomedical, and life sciences industries. The company's main product, VisualShare, is a web-based platform that facilitates image sharing, review processes, and documentation of results. It enables healthcare professionals such as cardiologists, ophthalmologists, and pathologists to collaborate effectively, even across geographically distant locations. VisualShare's technology supports a framework for image-centric collaboration, storing all relevant information in a single record for various stakeholder needs, including quality assurance and audit purposes. The company is based in Salt Lake City, Utah, and operates as a subsidiary of XIFIN, Inc. VisualShare has also licensed technology from the University of Utah, which contributes to its innovative approach in the field.
MediProPharma
Angel Round in 2010
MediProPharma, Inc. operates as a biotechnology company. The company was incorporated in 2006 and is based in Midvale, Utah.
Q Therapeutics
Venture Round in 2008
Q Therapeutics is a development stage company based in Salt Lake City, Utah, focused on creating human cell-based therapies for degenerative diseases affecting the brain and spinal cord. The company is primarily engaged in the development of Q-Cells, a novel stem cell therapy designed to treat a range of conditions, including amyotrophic lateral sclerosis (ALS), multiple sclerosis, transverse myelitis, traumatic spinal cord injury, and Parkinson's disease. Additionally, Q Therapeutics aims to address other neurological disorders such as Alzheimer’s disease, traumatic brain injury, cerebral palsy, leukodystrophies, central nervous system storage diseases, and peripheral neuropathies. The therapies developed by Q Therapeutics work by replacing the insulating myelin on damaged neurons and providing trophic support to restore and preserve normal neurological functions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.